Design Therapeutics reports Phase I/II RESTORE-FA trial outcomes
Design Therapeutics has reported data from the ongoing Phase I/II RESTORE-FA clinical trial assessing DT-216P2 in Friedreich ataxia (FA) patients.…
All articles by Salong Debbarma
Salong Debbarma
-
-
First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial
Triveni Bio has dosed the first healthy volunteers in its Phase I study of TRIV-573, a half-life extended bispecific antibody…
-
Ipsen reports sustained duration of effect in Phase II corabotase trial
Ipsen has announced Phase II corabotase data in glabellar lines, reporting sustained duration of effect and consistently high patient satisfaction. The first clinical…
-
Regeneron’s trial fails to reach statistical significance for primary endpoint
Regeneron Pharmaceuticals has reported that its Phase III trial assessing fianlimab (a LAG-3 inhibitor) and cemiplimab (a PD-1 inhibitor) for…
-
Tempus broadens collaboration with BMS for clinical trials
Tempus AI has expanded its strategic partnership with Bristol Myers Squibb (BMS) to optimise clinical trial designs across oncology and…
-
Massive Bio and Just Worldwide to expand cancer trial access
Massive Bio has signed a strategic partnership with Just Worldwide to connect more cancer patients to clinical studies. The collaboration…
-
QuartzBio secures Eir Partners investment for trial intelligence platform
QuartzBio has secured a strategic investment and majority ownership from private equity company Eir Partners to expedite its clinical trial…
-
Osel and partners launch Phase IIb FLIP-2 trial of Lactin-V
Osel, Imperial College London’s clinical trials unit and March of Dimes have launched the Phase IIb FLIP-2 trial, assessing the…
-
Enterprise’s Phase II trial of ETD001 meets primary endpoint in pwCF
Enterprise Therapeutics (Enterprise) has announced that its Phase II clinical trial of ETD001, an investigational inhaled epithelial sodium channel (ENaC)…
-
Alkermes reports encouraging data from Phase III study of Lumryz
Alkermes has reported positive top line data from the Phase III REVITALYZ study, assessing the investigational use of extended-release Lumryz…